A First-in-Human, Open-Label, Multicenter, Dose-Escalation Phase I Clinical Study of Single-Agent RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs RO-7172508 (Primary) ; RO-7172508 (Primary) ; Obinutuzumab; Tocilizumab
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Roche
- 07 Oct 2019 Status changed from discontinued to completed.
- 07 Aug 2019 Status changed from recruiting to discontinued.
- 25 Jun 2019 Planned End Date changed from 15 Jun 2021 to 22 Dec 2020.